How to Start Linzess (Linaclotide)
Start linaclotide at 290 mcg once daily for IBS-C or 145 mcg once daily for chronic constipation, taken on an empty stomach at least 30 minutes before the first meal of the day. 1
Dosing by Indication
The starting dose depends entirely on your diagnosis:
- IBS-C (Irritable Bowel Syndrome with Constipation): 290 mcg once daily 1
- Chronic Idiopathic Constipation (CIC): 145 mcg once daily (or 72 mcg once daily if tolerability is a concern) 1
- Functional Constipation in pediatrics (ages 6-17): 72 mcg once daily 1
The distinction between IBS-C and CIC is critical here. If your patient has predominant abdominal pain along with constipation, use the 290 mcg dose for IBS-C. If constipation is the primary issue without significant pain, use 145 mcg for CIC 2. The 2023 AGA-ACG guidelines emphasize that linaclotide improves both bowel symptoms and abdominal discomfort/bloating, making it particularly useful when these symptoms coexist 2.
Administration Instructions
Critical timing: Administer on an empty stomach at least 30 minutes before the first meal, at approximately the same time each day 1. This timing is non-negotiable for optimal efficacy.
Capsule administration:
- Swallow capsules whole—do not crush or chew 1
- If a dose is missed, skip it and resume at the regular time; never double dose 1
For patients unable to swallow capsules, you have three FDA-approved options 1:
- With applesauce: Open capsule, sprinkle beads on 1 teaspoon room-temperature applesauce, consume immediately without chewing beads
- With water (oral): Open capsule into 30 mL room-temperature water, swirl 20 seconds, swallow immediately (beads won't dissolve—this is normal), add another 30 mL to remaining beads and repeat
- Via NG/G-tube: Mix beads with 30 mL water, draw into catheter-tipped syringe, dispense rapidly (10 mL/10 seconds), repeat with additional 30 mL, flush tube with minimum 10 mL water
Dose Adjustment Strategy
For CIC patients with tolerability concerns, the 72 mcg dose is an appropriate starting point 1, 3. A 2018 trial demonstrated that 72 mcg significantly improved bowel symptoms with lower discontinuation rates due to diarrhea (2.4% vs 3.2% for 145 mcg) 3. This lower dose met primary efficacy endpoints while maintaining better tolerability.
Do not titrate up routinely—the evidence supports starting at the target dose based on indication 4. The trials that established efficacy used fixed doses without titration.
Setting Expectations
Onset of action: Effects typically manifest within 2 days in responders, though full assessment requires 6-12 weeks 2. The pivotal trials used 12-week treatment periods 4.
Diarrhea management: This is the most common adverse event (16.3% vs 2.3% placebo in IBS-C trials) 4. Importantly:
- Most cases are mild to moderate 4, 2
- Discontinuation due to diarrhea occurs in only 3.4% of patients 4
- No serious adverse events from diarrhea were reported in major trials 4
- Taking with food may reduce nausea but contradicts the empty stomach requirement—maintain the 30-minute pre-meal timing 2
Contraindications and Warnings
Absolute contraindications 1:
- Age <2 years (BLACK BOX WARNING: risk of fatal dehydration)
- Known or suspected mechanical GI obstruction
Special populations:
- Ages 2-5 years: Avoid use (safety not established) 1
- Ages 6-17 years: Use 72 mcg dose only 1
- Elderly (≥65 years): No dose adjustment needed; efficacy comparable to younger patients 2
- Hepatic impairment: No adjustment needed (minimal systemic absorption) 5
Clinical Context from Guidelines
The 2022 AGA guidelines on IBS-C provide a strong recommendation for linaclotide use, supported by high-quality evidence from 4 RCTs involving 2,612 patients 4. The 2023 AGA-ACG guidelines on chronic constipation similarly provide a strong recommendation with moderate certainty of evidence 2.
Key efficacy data supporting these recommendations 4, 2:
- 34% of IBS-C patients achieved FDA responder status (≥30% pain reduction + ≥1 CSBM/week increase) vs 18.8% placebo
- Increased CSBMs by 1.37/week in CIC patients
- Improved stool consistency, straining, bloating, and quality of life
When to use linaclotide: The guidelines position it for patients who don't respond adequately to OTC laxatives, though it can be used as first-line prescription therapy for IBS-C given its mechanism-based approach targeting both pain and constipation 2, 6.
Common Pitfalls to Avoid
- Wrong timing: Taking with food reduces efficacy—emphasize the 30-minute pre-meal requirement
- Wrong dose for indication: Using 145 mcg for IBS-C or 290 mcg for simple constipation—match dose to diagnosis
- Premature discontinuation: Patients may stop due to early diarrhea before experiencing full benefit—counsel about transient nature
- Crushing capsules: This destroys the drug delivery system—use alternative administration methods if swallowing is difficult
- Pediatric use errors: Never use in children <6 years; only 72 mcg dose approved for ages 6-17